Table 4 Bivariate and Multivariate analysis for baseline clinical characteristics of patients in four selected health facilities of Kembata and Hadiya zones for Death (real case assumptions), 2007 – 2011

Sex

Female

429

1

1

Male

301

1.69 (1.69, 2.12)

1.22 (0.70, 2.10)

Spouse treatment status

Enrolled ART

179

1

1

Not Enrolled ART

254

2.54 (1.26, 5.13)

1.31 (0.29, 5.98)

Unknown

212

2.88 (1.41, 5.85)

1.32 (0.61, 2.86)

Smoke Tobacco

No

636

1

1

Yes

94

1.70 (1.00, 2.87)

0.40 (0.12, 1.36)

Use other substances

No

631

1

1

Yes

98

1.87 (1.13, 3.09)

1.12 (0.66, 1.54)

Attending HIV related education

No

372

1

1

Yes

358

0.68 (0.44, 1.05)

0.87 (0.66, 1.90)

Understanding HIV prophylaxis

Poor

374

1

1

Good

356

0.70(0.46, 1.06)

0.65 (0.45, 1.89)

Understanding of Adherence to HIV medication

Poor

419

1

1

Good

311

0.68 (0.44, 1.05)

0.68 (0.38, 1.44)

OIs before initiation of ART

No OIs

249

1

Only one OIs

280

1.27 (0.78, 2.07)

NA

≥2 OIs

201

0.73 (0.44, 1.23)

NA

TB status before initiation of ART

Absent

711

1

Present

19

3.33 (1.54, 7.20)

1.25 (0.68, 1.54)

OIs after initiation of ART

No OIs

534

1

1

Only one OIs

170

2.38 (1.51, 3.75)

1.24 (1.06, 1.89)

≥2OIs

26

10.90 (6.13, 19.37)

3.35 (1.46,7.69)

TB after initiation of ART

Absent

662

1

1

Present

68

1.82 (1.03, 3.22)

1.428 (1.28, 3.39)

Past prophylaxis

Not Received

269

1

Received

461

0.88 (0.59, 1.33)

NA

Functional status

Working

495

1

1

Ambulatory

194

2.81 (1.79, 4.41)

1.79 (1.05, 3.07)

Bedridden

39

6.32 (3.42, 11.700)

3.40 (1.61, 7.21)

WHO clinical stage

Stage I

101

1

1

Stage II

148

2.32 (0.64, 8.41)

NA

Stage III

413

5.06 (1.59, 16.13)

2.01 (1.02, 4.35)

Stage IV

62

8.58 (2.46, 19.87)

2.42 (1.19, 5.86)

Hemoglobin by g/dl

<10

110

1

1

≥10

620

0.17 (0.11, 0.26)

0.22 (0.14, 0.37)

CD4 counts at baseline

<51 cells/mm³

106

1

1

51 –200 cells/mm³

398

0.23 (0.15, 0.35)

0.26 (0.15, 0.45)

201 –350 cell/mm³

195

0.13 (0.07, 0.25)

0.20 (0.09, 0.43)

>350 cell/mm³

31

0.06 (0.01, 0.46)

0.12 (0.02, 0.91)

Weight at baseline

≤45

160

1

1

46 –55

329

0.58 (0.37, 0.93)

0.52 (0.29, 1.93)

56 – 65

184

0.39 (0.21, 0.70)

0.51 (0.28, 1.18)

>65

57

0.24 (0.07, 0.75)

0.55 (0.16, 1.19)

Regimen at baseline

1a = d4t-3TC-NVP

268

1

1

1b = d4t-3TC-EFV

67

0.71 (0.32, 1.58)

NA

1c = AZT-3TC-NVP

197

0.55 (0.31, 0.97)

1.63 (0.87, 3.05)

1d = AZT-3TC-EFV

51

0.84 (0.36, 1.98)

NA

TDF-3TC_NVP

141

1.39 (0.82, 2.35)

NA

Regimen Adherence

Good

675

1

1

Fair

18

4.36 (2.00, 9.50)

1.66 (0.59, 4.62)

Poor

37

5.94 (3.49, 10.14)

2.70 (1.40, 5.20)